Spots Global Cancer Trial Database for relapsed hematologic malignancy
Every month we try and update this database with for relapsed hematologic malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Extended Analysis for Leukemia/Lymphoma Treatment | NCT03096821 | Relapsed Hemato... | ngFDS selected ... | 18 Years - | Medical University of Vienna | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | NCT05205252 | Relapsed Hemato... Refractory Hema... | Tazemetostat Tafasitamab Lenalidomide Acalabrutinib Daratumumab (In... Mosunetuzumab Daratumumab (Su... Hyaluronidase-F... Pomalidomide Dexamethasone 2... | 18 Years - | Ipsen | |
| Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant | NCT03413800 | Relapsed Hemato... Multiple Myelom... | Lenalidomide-De... | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma | NCT05956457 | Multiple Myelom... Relapsed Hemato... | Digital Health ... Fitbit | 18 Years - | Pack Health | |
| A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | NCT03560882 | Malignant Disea... Solid Tumor Acute Myeloid L... Myelodysplastic... Cancer Relapsed Hemato... | Atorvastatin | 18 Years - | University of Kansas Medical Center | |
| Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant | NCT03821519 | Relapsed Hemato... | donor-derived C... | 18 Years - | A.O. Ospedale Papa Giovanni XXIII | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | NCT02259348 | Acute Lymphobla... Acute Myeloid L... Myeloid Sarcoma Chronic Myeloge... Juvenile Myelom... Myelodysplastic... Non-Hodgkin Lym... | Cyclophosphamid... Fludarabine G-CSF Interleukin-2 Melphalan Thiotepa Rituximab Natural killer ... T-cell depleted... CD45RA-depleted... | - 21 Years | St. Jude Children's Research Hospital | |
| Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy | NCT04327583 | Advanced or Met... Relapsed Hemato... | IPPACTTO | 18 Years - | Institut Cancerologie de l'Ouest | |
| A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | NCT03328078 | Relapsed Hemato... Refractory Hema... Relapsed Primar... Refractory Prim... | Emavusertib ibrutinib | 18 Years - | Curis, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
